Releases on AIM
  Most Recent Reports
   
   
News Releases

Bodisen Biotech, Inc. Announces First Annual Town Hall Meeting in Xinjiang Province

SHAANXI, China--(BUSINESS WIRE)--Bodisen Biotech, Inc. (the ``Company'') (LSE:BODI.L - News) (Pink Sheets:BBCZ - News) (website: http://www.bodisen.com) announced today that the Companyí»s First Annual Town Hall meeting will be held Tuesday, December 2, 2008 at 10:00 a.m. at the Ying Hotel, Jun Ken Road, Alaer City, Xinjiang, China. The Company will review the 2007 financial performance and plans for continue growth in 2008. The current and future financial health of the Company will be discussed, and the possibility of acquiring new business opportunities.


The Company will discuss the recent dismissal of the class action lawsuit.


The Company will also focus on the forward vision of the Company based on the economic status of China and how Bodisen may be affected. All Shareholders of Bodisen Biotech are invited to join the President, CEO and key management for a full day of corporate overview, updates and Q&A.


About Bodisen Biotech, Inc.


Bodisen Biotech, Inc. is a leading manufacturer of liquid and organic compound fertilizers, pesticides, insecticides and agricultural raw materials certified by the Petroleum Chemical Industry Administrative office of China (Chemical Petroleum Production Administrative Bureau), Shaanxi provincial government and Chinese government. The Company is headquartered in Shaanxi province and is a Delaware corporation. The Company's environmentally friendly ``green'' products have been proven to improve soil and plant quality and to increase crop yields.


SafeHarbor Statement


This press release may contain forward-looking statements within the meaning of the ``safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Bodisen Biotech, Inc. management and are subject to a number of factors and uncertainties, and the outcome of events may differ materially from those described in the forward-looking statements.


Contact:

Bodisen Biotech, Inc.

Investor Relations

Joseph Visconti, U.S. Representative, 561-832-8878

Joseph@ivaluerich.com


 


Copyright © 2004 bodisen.com